ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2021 Influenza A Virus, H5N1 Subtype Infections Drug Development Research Report - ResearchAndMarkets.com

August 19, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Aug 19, 2021--

The “Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) - Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

ADVERTISEMENT

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 5, 1, 20, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 5 and 1 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

ADVERTISEMENT

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Influenza A Virus, H5N1 Subtype Infections - Overview
  • Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
  • Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
  • Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
  • Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
  • Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
  • Appendix

Companies Mentioned

  • Abivax SA
  • Abzyme Therapeutics LLC
  • Akshaya Bio Inc
  • AlphaVax Inc
  • Altimmune Inc
  • Aphios Corp
  • AusBio Ltd
  • BiondVax Pharmaceuticals Ltd
  • Chicago Biosolutions Inc
  • CHO Pharma Inc
  • Cocrystal Pharma Inc
  • Curevac NV
  • CytoAgents Inc
  • Declion Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • FluGen Inc
  • Gamaleya Federal Research Center of Epidemiology and Microbiology
  • Gamma Vaccines Pty Ltd
  • Global BioLife Inc Ltd
  • Greffex Inc
  • Inovio Pharmaceuticals Inc
  • Medicago Inc
  • Medigen Inc
  • NanoViricides Inc
  • New Amsterdam Sciences Inc
  • NuGenerex Immuno-Oncology Inc
  • PeptiDream Inc
  • Pneumagen Ltd
  • Replikins Ltd
  • Revelation Biosciences Inc
  • Seqirus Ltd
  • Shionogi & Co Ltd
  • TechnoVax Inc
  • Tria Bioscience Corp
  • Vacthera BioTech GmbH
  • Vaxart Inc
  • Vaxine Pty Ltd
  • Virion Biotherapeutics

For more information about this report visit https://www.researchandmarkets.com/r/ury1rn

View source version on businesswire.com:https://www.businesswire.com/news/home/20210819005530/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 08/19/2021 10:08 AM/DISC: 08/19/2021 10:08 AM

http://www.businesswire.com/news/home/20210819005530/en